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Improved patient and graft survival using
cyclosporin A in cadaver renal
transplantation
R W G Johnson
SUMMARY
In two consecutive prospective randomised trials cyclosporin A has been
compared with conventional immunosuppressive therapy (azathioprine and
steroids) and with cyclosporin combined with steroids. The present report is a 4
year review and includes 165 patients.
Cyclosporin A alone had a significant advantage over conventional therapy at
both I and 3 years (p =0.02) for both patient and graft survival. No significant
difference was seen when cyclosporin was combined with steroids. Nephro-
toxicity was the most troublesome side-effect of cyclosporin A - but this
resolved spontaneously on withdrawal of the drug.
INTRODUCTION
Since October 1980, 165 patients have been entered into two consecutive
prospective randomised trials of the imunosuppressive drug cyclosporin A and
have been followed up for a minimum of six months and a maximum of 4.5
years. In the first study cyclosporin A is compared with a conventional immuno-
suppressive regime of azathioprine and steroids. In the second, cyclosporin A
alone is compared with cyclosporin A plus steroids. These studies have been
conducted inasingle centre withalarge experience (600 patients)ofconventional
immunosuppressive therapy following cadaver renal transplantation.
PATIENTS AND METHODS
Only non-diabetic recipients of first and second cadaver renal grafts were
considered. Every patient had previously received at least one blood transfusion;
grafts were allocated on the basis of the least number of HLA-AB and DR
mismatches. All patients received 500 mg methylprednisolone intravenously
intra-operatively. Urine output was monitored hourly for the first six hours post-
operatively and if it equalled or exceeded 50 ml/hr the recipient was entered into
the trial by drawing a card to determine immunosuppressive therapy.
Group I Conventional therapy:
Azathioprine 3 mg/kg body weight
Soluble prednisolone 0.5 mg/kg body weight (to a maximum dose of
30 mg daily)
Group 11 Cyclosporin A alone:
Cyclosporin A was started as a continuous intravenous infusion
6 mg/kg body weight for 12 hr or until drugs could be accepted orally.
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Thereafter it was given in divided doses totalling 17 mg/kg/day in
milk. The dose was reduced by 2 mg/kg at 2 weeks and 4 weeks, and
then reduced monthly down to 5 mg/kg. In the event of toxic side-
effects the dose was reduced by one-third. Iftoxicity continued or was
intolerable the patients were switched to conventional therapy.
Group III Cyclosporin A plus steroids:
This group received cyclosporin A as above; in addition they were
given low dose soluble prednisolone 0.25 mg/kg (to a maximum dose
of 15 mg daily).
Acute rejection had to be distinguished from nephrotoxicity; this was most often
accomplished by biopsy. Confirmed rejection was treated by daily injections of
1 g methylprednisolone for 3 days. It was a condition of the trial that only two
rejection episodes should be treated in the cyclosporin A group and a maximum
of 6 g steroid given. If graft function remained impaired or there was further
deterioration the patients was switched to conventional therapy.
There were no serious imbalances of selection in any of the treatment groups.
Age and sex were similarly distributed. HLA-AB and DR mismatches were close
to 1.5 in the conventional group and 1.8 in the cyclosporin treated groups. All
patients who lost their grafts and returned to dialysis were followed up for 1 year
and included in the mortality data.
RESULTS
For ease of presentation and because the results were exactly the same the two
cohorts of patients treated with cyclosporin alone have been combined.
Graft survival for the three treatment groups is shown in Table 1. All patients who
initially received cyclosporin are included in the graft survival analysis for the
cyclosporin group, regardlessofwhetherornottheyweresubsequently converted
to conventional therapy ('intention to treat' principle). One year graft survival was
80.2 % (65 of 81 grafts) in the cyclosporin alone group; this did not change
significantly when steroids were added with survival at 78.6% (22 of 28 grafts).
Both groups did significantly better than the conventional group where graft
survival was 66% (37 of 56).
TABLE I
Graft survival
Group No. 3 months 1 year 2 years 3 years
Azathioprine
and steroids 56 78% 65% 57% 57%
Cyclosporin A alone 54
90% 80.2% 78.4% 78.4%
Cyclosporin A alone 27
Cyclosporin A
and steroids 28 95.2% 78.6% 74.9% 74.9%
Cyclosporin A alone and cyclosporin A with steroids are significantly better than azathioprine and
steroids at every stage (p = 0.02).
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Included in the cyclosporin alone group are 42 patients (51.8%) who were
converted to conventional therapy (Table 11) either because they required more
than 6 g methylprednisolone for treatment of acute rejection (16 patients trial
condition) or because of side-effects of cyclosporin (26 patients). One year graft
survival in this sub-group is 76.2% (32 of 42 grafts): this is significantly better
than for conventional treatment (p=.02). The incidence of conversion to
conventional therapy was much lower (25% or 7 of 28), when steroids were
combined with cyclosporin (Table 111). This was because cyclosporin toxicity was
reduced; conversion for rejection remained the same. Overall only one of 29
grafts was lost following conversion for toxicity whereas 13 out of 20 were lost
when conversion was due to rejection.
TABLE II
Conversion from cyclosporin A to conventional therapy
(No. atrisk=81)
Reason No. Grafts lost
Toxicity 26 1
Rejection 16 9 (56.25%)
42 (51.8%) 10 (23.8%)
TABLE III
Effect ofconcomitant steroid therapy on rate ofconversionfrom cyclosporin A to
conventional therapy
Reason for conversion Cyclosporin A alone Cyclosporin A +steroids
(No. at risk 27) (No. at risk 28)
No. Grafts lost No. Grafts lost
Toxicity 11 0 4 1
Rejection 2 1 3 3
13(48%) 1 7(25%) 4
In the cyclosporin alone group there were 3 deaths (Table IV), only one of which
was related to immunosuppression. There were two deaths in the cyclosporin
plus steroids group, one of which was due to viraemia. The highest mortality was
in the conventional therapy group (6 of 56). Four of these could be attributed to
immunosuppression.
The commonest side-effects amongst the cyclosporin treated patients were
hirsutism 44%, fine tremor 39%, gingival hypertrophy 28%, nephrotoxicity
25%, hyperaesthesia 1 1 % and hyperkalaemia 9%. Most of these side-effects
were minorand allwere dose-related. They disappeared rapidlywhen cyclosporin
was withdrawn or its dose reduced sharply. Nephrotoxicity was the commonest
reason for conversion to conventional therapy. In patients on conventional
therapy the commonest side-effects related to steroid therapy: cushingoid
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TABLE IV
Causes of death
Treatment Days Graft
group Diagnosis post.op status
Cyclosporin A 1. myocardial infarction 350 days functioning
alone 2. cerebral thrombosis 115 days functioning
3. peritonitis (CAPD) 200 days lost
Azathioprine 1. sepsis 170 days lost
+ 2. cerebral thrombosis 41 days functioning
steroids 3. carcinoma pancreas 288 days functioning
4. viraemia (CMV) 43 days lost
5. viraemia (Herpes) 9 days lost
6. sepsis 130 days lost
Cyclosporin A 1. viraemia 31 days lost
+ 2. sclerosing peritonitis 252 days functioning
steroids (CAPD)
appearance 54%, peptic ulceration 2% and diabetes 2%. These effects were aiso
present when steroids were combined with cyclosporin. There was no difference
in the frequency of bacterial, viral and fungal infections in the three groups but
there was a difference in incidence of life-threatening infections. There were no
life-threatening infections among the patients with cyclosporin alone whereas
there were 8 in the conventional group resulting in 4 deaths and there were 3
amongst patients treated with cyclosporin and steroids resulting in one death.
DISCUSSION
These results confirm the view that renal allograft survival is greater in patients
treated with cyclosporin alone as a first line immunosuppressive drug than in
those treated with azathioprine and steroids. Our main interest in cyclosporin was
its steroid-sparing potential; the significant improvement in graft survival without
the side-effects of steroids was a bonus. The results we obtained for one year
graft survival in patients treated with azathioprine and steroids accurately
represent our previous experience with these drugs over the last 10 years.
Improved graft survival (80.2%) with cyclosporin alone is similar to results
obtained by the Cambridge groupl1 2 and by the European Multicentre Study.3
Cyclosporin A differs greatlyfrom all previously used immunosuppressive agents.
The main problem in clinical use is distinguishing between nephrotoxicity and
rejection. Most of the classical inflammatory features of acute rejection are
absent. Serum creatinine is the only easily measurable determinant. Cyclosporin
nephrotoxicity has been well documented4 5 and it is known to disappear on
withdrawal of the drug. In this study many people were treated for rejection and
then converted to conventional therapy as a condition ofthetrial, only to discover
in retrospect that nephrotoxicity had been the problem. This resulted in an
unacceptably high rate of conversion, 51.8% to conventional therapy. Sixteen
patients (20.15%) were converted for rejection and to avoid the consequences
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of over-immunosuppression reported by the Cambridge group.' Of these, 10
subsequently lost their grafts. Twenty-five patients (30.8%) were converted for
toxicity without graft loss. These changes reflect inexperience in the use of
cyclosporin and also the lack of a meaningful assay. There is now evidence that
much lower doses of cyclosporin can be used in conjunction with careful whole
blood monitoring of the drug. Under these conditions improved graft survival is
maintained and toxicity minimised. Our approach was totry and exclude rejection
by biopsy and then reduce the dose by one-third. If a satisfactory result was
obtained the dose was further reduced until the side-effects disappeared
(therapeutic titration).
Graft survival results in the sub-group of patients converted to conventional
therapy was 76.2% ; this wasstill significantly betterthan the conventional group,
and it is of particular interest that only one graft was lost when conversion was
because of toxicity.
Steroids were combined with cyclosporin to see if graft survival could be further
improved and in particularto see ifnephrotoxicity was reduced. Graft survival was
not significantly different when cyclosporin was given with maintenance steroids
(78.6%) butthe rate ofconversion fortoxicity wassignificantly reduced, 14.28%
compared with 40.7%. Conversion for rejection was the same in the two groups.
This advantage for maintenance steroids hasto be balanced againstthe increased
rate of steroid side-effects for no improvement in graft survival.
In these studies we have limited entry to recipients with primary renal failure
which excluded diabetic subjects and only included grafts that exhibited prompt
diuresis. This was done in order to minimise the variables. Clearly the steroid-
sparing aspect of cyclosporin therapy should have advantages in the treatment of
diabetics. Very few exclusions were made on grounds of no primary diuresis.
74% of kidneys used in this study were machine-perfused and, contrary to the
Canadian Multicentre Trial Report,6 this appears to have improved the rate of
entry and in no way adversely affected the outcome. Cyclosporin A alone has
now become our first choice immunosuppressive agent. We no longer convert
for persistent rejection, preferring loss of the graft if necessary, and we are
attempting to reduce toxicity by daily monitoring of whole blood trough levels of
the drug.
I acknowledge the significant contributions made to this study by Mr M H Wise, Mr A Bakran, Mr C G
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